Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6111-8.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
Biomarkers, Tumor
Boronic Acids
Bortezomib
Carcinoid Tumor
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Neuroendocrine Tumors
Pancreatic Neoplasms
Protease Inhibitors
Proteasome Inhibitors
Pyrazines
Time Factors
Treatment Outcome

authors with profiles

Hedy Kindler